How have ITRM shares performed in 2023?

Iterum Therapeutics' stock was trading at $0.84 on January 1st, 2023. Since then, ITRM stock has increased by 152.4% and is now trading at $2.12. View the best growth stocks for 2023 here .

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 60,100 shares, an increase of 22.9% from the October 31st total of 48,900 shares. Based on an average daily trading volume, of 89,900 shares, the short-interest ratio is presently 0.7 days. Approximately 0.5% of the company's stock are sold short. View Iterum Therapeutics' Short Interest .

When is Iterum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our ITRM earnings forecast .

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) posted its quarterly earnings results on Friday, November, 12th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $1.80 by $1.50. During the same quarter last year, the firm earned ($5.10) earnings per share.

When did Iterum Therapeutics' stock split?

Iterum Therapeutics shares reverse split before market open on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE) , Viking Therapeutics (VKTX) , Acasti Pharma (ACST) , Axsome Therapeutics (AXSM) , Innovate Biopharmaceuticals (INNT) , OPKO Health (OPK) , VYNE Therapeutics (VYNE) , Fulcrum Therapeutics (FULC) , Ocugen (OCGN) .

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Iterum Therapeutics Stock Price, News & Analysis (NASDAQ:ITRM)

$2.12

+0.24 (+12.77%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.83
▼
$2.12
50-Day Range: $0.65
▼
$2.30
52-Week Range: $0.60
▼
$2.50

Volume: 169,034 shs
Average Volume: 77,913 shs
Market Capitalization: $27.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Iterum Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.51
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$56,500 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.93) to ($3.05) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.20 out of 5 stars

Medical Sector

921st out of 949 stocks

Pharmaceutical Preparations Industry

427th out of 437 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Iterum Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
0.47% of the float of Iterum Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Iterum Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Iterum Therapeutics has recently increased by 22.90%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Iterum Therapeutics does not currently pay a dividend.
Dividend Growth
Iterum Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ITRM.

2.5

News and Social Media Coverage

News Sentiment
Iterum Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Iterum Therapeutics this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for ITRM on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iterum Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $56,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Iterum Therapeutics is held by insiders.
Percentage Held by Institutions
Only 3.39% of the stock of Iterum Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Iterum Therapeutics are expected to decrease in the coming year, from ($2.93) to ($3.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iterum Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iterum Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Iterum Therapeutics has a P/B Ratio of 8.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Iterum Therapeutics Stock (NASDAQ:ITRM)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

ITRM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ITRM Stock News Headlines

November 29, 2023 | msn.com

Iterum Therapeutics director discloses purchase of 20K shares

November 28, 2023 | americanbankingnews.com

Insider Buying: Iterum Therapeutics plc (NASDAQ:ITRM) Director Acquires 20,000 Shares of Stock

December 1, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 15, 2023 | finance.yahoo.com

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript

November 15, 2023 | finance.yahoo.com

Q3 2023 Iterum Therapeutics PLC Earnings Call

November 14, 2023 | finanznachrichten.de

Iterum Therapeutics PLC: Iterum Therapeutics Reports Third Quarter 2023 Financial Results

November 14, 2023 | msn.com

Iterum Therapeutics GAAP EPS of -$0.30

November 14, 2023 | benzinga.com

Recap: Iterum Therapeutics Q3 Earnings

December 1, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 14, 2023 | finance.yahoo.com

Iterum Therapeutics Reports Third Quarter 2023 Financial Results

November 13, 2023 | msn.com

Iterum Therapeutics Q3 2023 Earnings Preview

November 13, 2023 | benzinga.com

Earnings Outlook For Iterum Therapeutics

November 7, 2023 | finance.yahoo.com

Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023

November 5, 2023 | morningstar.com

Iterum Therapeutics PLC ITRM

October 24, 2023 | finance.yahoo.com

Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

October 12, 2023 | finance.yahoo.com

Iterum Therapeutics to Present Data at IDWeek 2023

August 12, 2023 | finance.yahoo.com

Q2 2023 Iterum Therapeutics PLC Earnings Call

August 11, 2023 | finanznachrichten.de

Iterum Therapeutics PLC: Iterum Therapeutics Reports Second Quarter 2023 Financial Results

August 11, 2023 | finance.yahoo.com

Iterum Therapeutics Reports Second Quarter 2023 Financial Results

August 10, 2023 | benzinga.com

Iterum Therapeutics's Earnings: A Preview

August 4, 2023 | finance.yahoo.com

Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023

July 11, 2023 | finance.yahoo.com

ITRM - Iterum Therapeutics plc

June 12, 2023 | finance.yahoo.com

Iterum Therapeutics to Present Data at ASM Microbe 2023

May 12, 2023 | finanznachrichten.de

Iterum Therapeutics PLC: Iterum Therapeutics Reports First Quarter 2023 Financial Results

May 12, 2023 | finance.yahoo.com

Iterum Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023 | finance.yahoo.com

Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat

May 5, 2023 | marketwatch.com

8-K: Iterum Therapeutics plc

See More Headlines

Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ITRM
CUSIP: N/A
CIK: 1659323
Web: www.iterumtx.com
Phone: (531) 669-4820
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,430,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -216.28%
Return on Assets: -57.67%

Debt

Debt-to-Equity Ratio: 3.63
Current Ratio: 2.35
Quick Ratio: 2.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.26 per share
Price / Book: 7.81

Miscellaneous

Outstanding Shares: 13,050,000
Free Float: 12,502,000
Market Cap: $26.49 million
Optionable: Not Optionable
Beta: 1.63

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Corey N. Fishman (Age 58)
President, CEO & Director
Comp: $1.37M
Ms. Judith M. Matthews (Age 53)
Chief Financial Officer
Comp: $778.82k
Dr. Michael W. Dunne M.D. (Age 63)
Strategic Advisor & Director
Comp: $168.15k
Dr. Sailaja Puttagunta M.D. (Age 54)
Chief Medical Officer
Comp: $755.89k
Mr. Tom Loughman Ph.D.
Senior Vice President of Technical Operations
Ms. Louise Barrett
Senior Vice President of Legal Affairs & Secretary
Dr. Steven I. Aronin M.D.
Senior VP & Head of Clinical Development

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ITRM Stock Analysis - Frequently Asked Questions

How have ITRM shares performed in 2023?: Iterum Therapeutics' stock was trading at $0.84 on January 1st, 2023. Since then, ITRM stock has increased by 152.4% and is now trading at $2.12.
View the best growth stocks for 2023 here.
Are investors shorting Iterum Therapeutics?: Iterum Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 60,100 shares, an increase of 22.9% from the October 31st total of 48,900 shares. Based on an average daily trading volume, of 89,900 shares, the short-interest ratio is presently 0.7 days. Approximately 0.5% of the company's stock are sold short.
View Iterum Therapeutics' Short Interest.
When is Iterum Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ITRM earnings forecast.
How were Iterum Therapeutics' earnings last quarter?: Iterum Therapeutics plc (NASDAQ:ITRM) posted its quarterly earnings results on Friday, November, 12th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $1.80 by $1.50. During the same quarter last year, the firm earned ($5.10) earnings per share.

When did Iterum Therapeutics' stock split?: Iterum Therapeutics shares reverse split before market open on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Iterum Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), Ocugen (OCGN).
When did Iterum Therapeutics IPO?: (ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.
How do I buy shares of Iterum Therapeutics?: Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ITRM) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial